Why a Singapore-based team is trying to sequence 100,000 Asian genomes

Why a Singapore-based team is trying to sequence 100,000 Asian genomes


Data from the U.S. National Library of Medicine suggests that 85% of genomics studies have been conducted in individuals of European descent.

Singapore-based project GenomeAsia 100K is working to address this representation disparity.

Almost a decade ago, it set the goal to sequence 100,000 Asian human genomes and create a genetic representation of Asian human variation.

“The project has two parts. Step one is to understand the genetic makeup of Asians as a whole entity, but then the second one is to find out which of those genetic markers that we newly discover are actually ethical markers and are not disease markers, as they have been described in the genomes of European descendants,” GenomeAsia 100K’s scientific director Stephan Schuster said in an interview with CNBC’s The Edge.

The project started off with a collection of pre-existing samples, and it has expanded its sample pool thanks to contributions from national collections, donors, clinicians and scientists.

To read the genomes, scientists extract the DNA from the samples and place it in a sequencer. The machine creates a high amount of data, which informs various demographic trends and allows for personalized medicine.

“The big advance is that we have entered the area of personalized medicine. The idea is, you would sequence the genome of a patient, and you will be able to tailor make a treatment, medication for that person. We try to build on that concept, and our key paradigm is, how can precision medicine be precise if you don’t precisely know who you are?” Schuster said.

“What we are trying to say is the pharmaceutical industry needs to make sure that the drugs that they develop are compatible. And the factor of ethnicity is currently not represented in precision medicine,” he added.

By expanding genomic data, underrepresented populations can benefit from improved clinical care, early detection of diseases and better diagnosis and drug design.

However, the genome diversification process is slow. Despite recent advancements, the GenomeAsia 100K project is far from reaching its initial goal and has, so far, sequenced 10,000 human genomes.

Watch the video above to learn more about GenomeAsia 100K and the importance of diversity in genomic research.



Source

5 takeaways from CNBC’s investigation into ‘nudify’ apps and sites
World

5 takeaways from CNBC’s investigation into ‘nudify’ apps and sites

Jessica Guistolise, Megan Hurley and Molly Kelley talk with CNBC in Minneapolis, Minnesota, on July 11, 2025, about fake pornographic images and videos depicting their faces made by their mutual friend Ben using AI site DeepSwap. Jordan Wyatt | CNBC In the summer of 2024, a group of women in the Minneapolis area learned that […]

Read More
Top Wall Street analysts favor these 3 stocks for their robust growth outlook
World

Top Wall Street analysts favor these 3 stocks for their robust growth outlook

The Nvidia logo is displayed on a building at Nvidia headquarters on Aug. 27, 2025 in Santa Clara, California. Justin Sullivan | Getty Images Despite macroeconomic uncertainties, several companies are well-positioned to deliver strong returns to investors from rapid technological advancements and artificial intelligence (AI) adoption. To pick attractive stocks with strong prospects, investors can […]

Read More
Trump is wielding the power of the state to back critical mineral companies. These are the possible next targets
World

Trump is wielding the power of the state to back critical mineral companies. These are the possible next targets

The Trump administration needs to strike multiple deals with U.S. miners to secure the nation’s supply chain against China, said Mark Chalmers, CEO of Energy Fuels, a miner focused on uranium and rare earth minerals. The Pentagon decision to take an equity stake in MP Materials, the largest U.S. rare earth miner, in July and […]

Read More